Prenatal cannabinoid exposure: why expecting individuals should take a pregnancy pause from using cannabinoid products
Open Access
- 11 October 2023
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Pediatrics
- Vol. 11, 1278227
Abstract
Cannabinoid use in all populations is increasing as legalization across the United States continues. Concerningly, there is a lack of caution provided by medical providers to pregnant individuals as to the impact the use of cannabinoids could have on the developing fetus. Research continues in both the preclinical and clinical areas, and is severely needed, as the potency of delta-9-tetrahydrocannabinol (THC), the primary psychoactive component of cannabis, has increased dramatically since the initial studies were completed. Thus far, clinical studies raise compelling evidence for short term memory deficits, impulse control issues, and attention deficiencies following prenatal cannabinoid exposure (PCE). These changes may be mediated through epigenetic modifications that not only impact the current offspring but could carry forward to future generations. While additional studies are needed, a pregnancy pause from cannabinoid products should be strongly recommended by providers to ensure the optimal health and well-being of our future generations.Keywords
This publication has 91 references indexed in Scilit:
- Type-1 Cannabinoid Receptor Signaling in Neuronal DevelopmentPharmacology, 2012
- Cannabinoid modulation of mother-infant interaction: is it just about milk?Reviews in the Neurosciences, 2012
- Maternal Cannabis Use Alters Ventral Striatal Dopamine D2 Gene Regulation in the OffspringBiological Psychiatry, 2011
- Marijuana-based Drugs: Innovative Therapeutics or Designer Drugs of Abuse?Molecular Interventions, 2011
- Developmental consequences of perinatal cannabis exposure: behavioral and neuroendocrine effects in adult rodentsPsychopharmacology, 2010
- Epigenetics: Definition, Mechanisms and Clinical PerspectiveSeminars in Reproductive Medicine, 2009
- Epigenetic regulation and fetal programmingBest Practice & Research Clinical Endocrinology & Metabolism, 2008
- The diverse CB1and CB2receptor pharmacology of three plant cannabinoids: Δ9‐tetrahydrocannabinol, cannabidiol and Δ9‐tetrahydrocannabivarinBritish Journal of Pharmacology, 2008
- Pharmacokinetics and Pharmacodynamics of CannabinoidsClinical Pharmacokinetics, 2003
- the ottawa prenatal prospective study (OPPS): Methodological issues and findings — it's easy to throw the baby out with the bath waterLife Sciences, 1995